TY - JOUR T1 - Extremely potent human monoclonal antibodies from convalescent Covid-19 patients JF - bioRxiv DO - 10.1101/2020.10.07.328302 SP - 2020.10.07.328302 AU - Emanuele Andreano AU - Emanuele Nicastri AU - Ida Paciello AU - Piero Pileri AU - Noemi Manganaro AU - Giulia Piccini AU - Alessandro Manenti AU - Elisa Pantano AU - Anna Kabanova AU - Marco Troisi AU - Fabiola Vacca AU - Dario Cardamone AU - Concetta De Santi AU - Linda Benincasa AU - Chiara Agrati AU - Maria Rosaria Capobianchi AU - Concetta Castilletti AU - Arianna Emiliozzi AU - Massimiliano Fabbiani AU - Francesca Montagnani AU - Lorenzo Depau AU - Jlenia Brunetti AU - Luisa Bracci AU - Emanuele Montomoli AU - Claudia Sala AU - Giuseppe Ippolito AU - Rino Rappuoli Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/10/07/2020.10.07.328302.abstract N2 - Human monoclonal antibodies are safe, preventive and therapeutic tools, that can be rapidly developed to help restore the massive health and economic disruption caused by the Covid-19 pandemic. By single cell sorting 4277 SARS-CoV-2 spike protein specific memory B cells from 14 Covid-19 survivors, 453 neutralizing antibodies were identified and 220 of them were expressed as IgG. Up to 65,9% of monoclonals neutralized the wild type virus at a concentration of >500 ng/mL, 23,6% neutralized the virus in the range of 100 - 500 ng/mL and 9,1% had a neutralization potency in the range of 10 - 100 ng/mL. Only 1,4% neutralized the authentic virus with a potency of 1-10 ng/mL. We found that the most potent neutralizing antibodies are extremely rare and recognize the RBD, followed in potency by antibodies that recognize the S1 domain, the S-protein trimeric structure and the S2 subunit. The three most potent monoclonal antibodies identified were able to neutralize the wild type and D614G mutant viruses with less than 10 ng/mL and are good candidates for the development of prophylactic and therapeutic tools against SARS-CoV-2.One Sentence Summary Extremely potent neutralizing human monoclonal antibodies isolated from Covid-19 convalescent patients for prophylactic and therapeutic interventions.Competing Interest StatementRino Rappuoli is an employee of GSK group of companies. Emanuele Andreano, Anna Kabanova, Dario Cardamone, Concetta De Santi, Ida Paciello, Noemi Manganaro, Elisa Pantano, Piero Pileri, Claudia Sala, Marco Troisi, Fabiola Vacca and Rino Rappuoli are listed as inventors of full-length human monoclonal antibodies described in Italian patent applications n. 102020000015754 filed on June 30th 2020 and 102020000018955 filed on August 3rd 2020. ER -